Edesa Biotech is trading at $4.67 (+5.42%) after rebounding in after-hours trading on August 21, 2026, following a sharp regular-session decline and the pricing of its $25 million underwritten offering.
- The offering was priced at $5.50 per share and accompanying warrant, with additional warrant coverage that may dilute shareholders.
- Proceeds will support working capital, research, development, and manufacturing expenses.
- The move came despite a broadly stronger market, suggesting the financing remains the key company-specific catalyst.